Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management.
Liebenberg D, Gordhan BG, Kana BD.
Front Cell Infect Microbiol. 2022 Sep 23;12:943545. doi: 10.3389/fcimb.2022.943545. eCollection 2022.
NIR-II AIE Luminogen-Based Erythrocyte-Like Nanoparticles with Granuloma-Targeting and Self-Oxygenation Characteristics for Combined Phototherapy of Tuberculosis.
Wang H, Li B, Sun Y, Ma Q, Feng Y, Jia Y, Wang W, Su M, Liu X, Shu B, Zheng J, Sang S, Yan Y, Wu Y, Zhang Y, Gao Q, Li P, Wang J, Ma F, Li X, Yan D, Wang D, Zou X, Liao Y.
Adv Mater. 2024 Sep;36(38):e2406143. doi: 10.1002/adma.202406143. Epub 2024 Jul 28.
Clinical management of combined tuberculosis and diabetes.
van Crevel R, Koesoemadinata R, Hill PC, Harries AD.
Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1404-1410. doi: 10.5588/ijtld.18.0340.
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.
Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P.
PLoS Med. 2018 Jul 3;15(7):e1002595. doi: 10.1371/journal.pmed.1002595. eCollection 2018 Jul.
Enhanced tuberculosis clearance through the combination treatment with recombinant adenovirus-mediated granulysin delivery.
Hao L, Ma J, Shi C, Lin X, Zhang Y, Jo-Lewis BN, Lei Q, Ullah N, Yao Z, Fan X.
Theranostics. 2020 Aug 8;10(22):10046-10056. doi: 10.7150/thno.48052. eCollection 2020.
A Mouse Model for Tuberculosis Combined With Inhalable Imiquimod-PLGA Nanocomposite Particles Based on Macrophage Phenotype.
Nii T, Takizawa S, Akita T, Yamashita C, Takeuchi I, Makino K.
In Vivo. 2022 Sep-Oct;36(5):2166-2172. doi: 10.21873/invivo.12942.
Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.
Agger EM.
Adv Drug Deliv Rev. 2016 Jul 1;102:73-82. doi: 10.1016/j.addr.2015.11.012. Epub 2015 Nov 17.
Tuberculosis disease among people with HIV: therapeutic advances.
Mave V, Paradkar M, Conradie F, Gupta A, Avihingsanon A, Meintjes G, Turkova A, Dooley KE, Chaisson RE.
Lancet HIV. 2025 May;12(5):e367-e381. doi: 10.1016/S2352-3018(25)00040-2. Epub 2025 Mar 24.
Recent advances in PLGA micro/nanoparticle delivery systems as novel therapeutic approach for drug-resistant tuberculosis.
Shao L, Shen S, Liu H.
Front Bioeng Biotechnol. 2022 Jul 22;10:941077. doi: 10.3389/fbioe.2022.941077. eCollection 2022.
Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.
Suman SK, Chandrasekaran N, Priya Doss CG.
Clin Microbiol Rev. 2023 Dec 20;36(4):e0008823. doi: 10.1128/cmr.00088-23. Epub 2023 Nov 30.
